“2024 was marked by significant progress towards achieving our vision of becoming the leading rare disease biopharmaceutical company focused on serious, rare genetic skin diseases,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Upon the close of our merger and concurrent private placement in December 2024, we were able to rapidly advance QTORIN rapamycin, our lead product candidate from the QTORIN platform, into the Phase 3 SELVA study for the treatment of microcystic lymphatic malformations and the Phase 2 TOIVA study for the treatment of cutaneous venous malformations. Microcystic LMs and cutaneous VMs are both serious, rare, and chronically debilitating genetic diseases for which QTORIN rapamycin has the potential to be the first FDA-approved therapy and standard of care in the U.S.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with a Buy at Stifel
- Palvella Therapeutics initiated with a Buy at JonesResearch
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Positive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential
- Palvella Therapeutics initiated with an Outperform at Scotiabank